deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04467905

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients With Atrial Fibrillation.

Sponsor: JSS Medical Research Inc.

Conditions Atrial Fibrillation
Interventions Etripamil Placebo
Updated 14 times since 2020 Last updated: Sep 16, 2024 Started: Nov 19, 2020 Primary completion: Aug 3, 2023 Completion: Aug 10, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04467905, this PHASE2 trial focuses on Atrial Fibrillation and remains completed. Sponsored by JSS Medical Research Inc., it has been updated 14 times since 2020, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Nov 2023 · 8 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Oct 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

▶ Show 9 earlier versions

  1. Mar 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  2. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE2

  3. Feb 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  4. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  5. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  6. Apr 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  9. Aug 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • JSS Medical Research Inc.
  • Milestone Pharmaceuticals Inc.
  • The Montreal Health Innovations Coordinating Center (MHICC)
Data source: Milestone Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Arnhem, Netherlands , Doetinchem, Netherlands , Emmen, Netherlands , Halifax, Canada , Hamilton, Canada , Helmond, Netherlands , Montreal, Canada , Newmarket, Canada , Ottawa, Canada and 6 more locations